Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study

Area of Science:

• Hematology
• Immunology
• Pediatric Medicine

Background:

• Immune tolerance induction (ITI) is a key treatment for congenital hemophilia A, achieving success in up to 70% of patients.
• Predictors of ITI response are understood, but factors influencing inhibitor recurrence post-ITI remain unclear.

Purpose of the Study:

• To investigate the association between clinical characteristics and inhibitor recurrence in hemophilia A patients who achieved tolerance post-ITI.
• Specifically, to assess the role of adherence to Factor VIII (FVIII) prophylaxis after ITI in inhibitor recurrence.

Main Methods:

• A multicenter retrospective cohort study analyzed 64 hemophilia A patients with FVIII levels <2% post-ITI.
• Kaplan-Meier method estimated cumulative inhibitor recurrence probability.
• Logistic regression assessed associations between clinical factors and recurrence.

Main Results:

• The cumulative probability of inhibitor recurrence at 1 and 5 years was 12.8% and 32.5%, respectively.
• Recurrent inhibitors were associated with immune modulation during ITI (OR 3.8) and FVIII recovery <85% post-ITI (OR 2.6).
• Adherence to post-ITI FVIII prophylaxis was not significantly associated with recurrence (OR 0.5).

Conclusions:

• Immune modulation during ITI and suboptimal FVIII recovery post-ITI are linked to increased inhibitor recurrence risk.
• Adherence to FVIII prophylaxis after successful ITI is not a primary factor in preventing inhibitor recurrence.